167 related articles for article (PubMed ID: 20408872)
1. Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia.
Tefferi A; Levitt R; Lasho TL; Knudson RA; Ketterling RP
Eur J Haematol; 2010 Jul; 85(1):86-7. PubMed ID: 20408872
[No Abstract] [Full Text] [Related]
2. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.
Cambier N; Renneville A; Cazaentre T; Soenen V; Cossement C; Giraudier S; Grardel N; Laï JL; Rose C; Preudhomme C
Leukemia; 2008 Jul; 22(7):1454-5. PubMed ID: 18288134
[No Abstract] [Full Text] [Related]
3. BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia.
Wang X; Tripodi J; Kremyanskaya M; Blouin A; Roda P; Hoffman R; Najfeld V
Blood; 2013 Feb; 121(7):1238-9. PubMed ID: 23411734
[No Abstract] [Full Text] [Related]
4. Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia.
Inami M; Inokuchi K; Okabe M; Kosaka F; Mitamura Y; Yamaguchi H; Dan K
Leukemia; 2007 May; 21(5):1103-4. PubMed ID: 17301812
[No Abstract] [Full Text] [Related]
5. [Successful treatment with dasatinib for polycythemia vera patient emerging BCR-ABL positive clone during 13 years of treatment].
Takizawa M; Yokohama A; Sekigami T; Koiso H; Ishizaki T; Mitsui T; Ogawa Y; Saitoh T; Handa H; Tsukamoto N; Murakami H; Nojima Y
Rinsho Ketsueki; 2014 Jun; 55(6):687-91. PubMed ID: 24975338
[TBL] [Abstract][Full Text] [Related]
6. Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation.
Caocci G; Atzeni S; Orrù N; Littera R; Culurgioni F; Marongiu F; La Nasa G
Leuk Res; 2010 Jan; 34(1):e27-9. PubMed ID: 19748671
[No Abstract] [Full Text] [Related]
7. A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders.
Bee PC; Gan GG; Nadarajan VS; Latiff NA; Menaka N
Int J Hematol; 2010 Jan; 91(1):136-9. PubMed ID: 20047097
[TBL] [Abstract][Full Text] [Related]
8. Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib.
Zhou A; Knoche EM; Engle EK; Fisher DA; Oh ST
Blood Cancer J; 2015 Oct; 5(10):e351. PubMed ID: 26430722
[No Abstract] [Full Text] [Related]
9. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib.
Woo SM; Huh CH; Park KC; Youn SW
J Dermatol; 2007 Oct; 34(10):724-6. PubMed ID: 17908148
[No Abstract] [Full Text] [Related]
10. A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2(V617F) myeloproliferative neoplasm.
Véronèse L; Tchirkov A; Richard-Pebrel C; Ledoux-Pilon A; Fleury J; Chaleteix C; Goumy C; Gouas L; Berger MG; Vago P; Bay JO; Tournilhac O
Leuk Res; 2010 Apr; 34(4):e94-6. PubMed ID: 19833389
[No Abstract] [Full Text] [Related]
11. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia.
Krämer A; Reiter A; Kruth J; Erben P; Hochhaus A; Müller M; Cross NC; Jones AV; Ho AD; Hensel M
Lancet Oncol; 2007 Jul; 8(7):658-60. PubMed ID: 17613428
[No Abstract] [Full Text] [Related]
12. Imatinib-lnduced agranulocytosis in a patient with chronic myelogenous leukemia in remission.
Khouri S; Kotliroff A; Lishner M; Amital H
Isr Med Assoc J; 2008 Apr; 10(4):320-1. PubMed ID: 18548994
[No Abstract] [Full Text] [Related]
13. Alterations of NFIA in chronic malignant myeloid diseases.
Bernard F; Gelsi-Boyer V; Murati A; Giraudier S; Trouplin V; Adélaïde J; Rey J; Olschwang S; Vainchenker W; Chaffanet M; Vey N; Mozziconacci MJ; Birnbaum D
Leukemia; 2009 Mar; 23(3):583-5. PubMed ID: 18754024
[No Abstract] [Full Text] [Related]
14. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
Garber K
J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
[No Abstract] [Full Text] [Related]
15. Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia.
Galanopoulos A; Papadhimitriou SI; Kritikou-Griva E; Georgiakaki M; Anagnostopoulos NI
Ann Hematol; 2009 Mar; 88(3):281-2. PubMed ID: 18726593
[No Abstract] [Full Text] [Related]
16. BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T).
Gattenlohner S; Völker HU; Etschmann B; Einsele H; Müller-Hermelink HK
Am J Hematol; 2009 May; 84(5):306-7. PubMed ID: 18951468
[No Abstract] [Full Text] [Related]
17. Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation.
Pingali SR; Mathiason MA; Lovrich SD; Go RS
Clin Lymphoma Myeloma; 2009 Oct; 9(5):E25-9. PubMed ID: 19858050
[TBL] [Abstract][Full Text] [Related]
18. JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia.
Campiotti L; Appio L; Solbiati F; Ageno W; Venco A
Leuk Res; 2009 Nov; 33(11):e212-3. PubMed ID: 19589593
[No Abstract] [Full Text] [Related]
19. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.
Thierry A; Dreyfus B; Bridoux F; Abou Ayache R; Milin S; Guilhot F; Touchard G
Nephrol Dial Transplant; 2007 Jun; 22(6):1791-2. PubMed ID: 17308316
[No Abstract] [Full Text] [Related]
20. Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis.
Jallades L; Hayette S; Tigaud I; Johnston A; Coiffier B; Magaud JP; Ffrench M
Leuk Res; 2008 Oct; 32(10):1608-10. PubMed ID: 18448166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]